Press release
Uromune (MV140) Drug Market Forecast and Analysis | Uromune (MV140) for uncomplicated Urinary Tract Infection: Market Size Analysis and Competitive Landscape by DelveInsight
Uromune (MV140) Drug Market Forecast and Analysis
The report also helps you to understand the Uromune (MV140) clinical and commercial landscape along with parameters like the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, special designations, and commercial and development activities.
Download Sample Report to know the https://www.delveinsight.com/sample-request/uromune-mv140-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Uromune (MV140) Report Key Features and Coverage
The report presents a thorough description of Uromune (MV140)'s characteristics and its use for uncomplicated Urinary Tract Infection, offering valuable insights into its drug's market potential. The report provides rich insights with respect to the competition in the market, as other emerging products that are in the advanced stage of pipeline development for uncomplicated Urinary Tract Infection are expected to give tough market competition to Uromune (MV140). It is predicted that the launch of late-stage emerging therapies in the near future will significantly impact the uncomplicated Urinary Tract Infection market, and this report will help to understand how Uromune (MV140) is going to compete against other drugs.
Uromune (MV140) Drug Summary
Uromune is a sublingual glycerinated suspension that contains whole cell-inactivated bacteria. It is designed to be self-administered by the patient through spraying over the sublingual area. The suspension consists of four strains of bacteria: Klebsiella pneumoniae, Escherichia coli, Enterococcus faecalis, and Proteus vulgaris, each comprising 25% of the total volume. The final concentration is 300 FTU/mL, equivalent to approximately 109 bacteria/mL.
MV140, also known as Uromune, is a polyvalent bacterial preparation composed of heat-inactivated bacteria responsible for most recurrent urinary tract infections (RUTI) in Europe. It stimulates human dendritic cells (DCs) to generate Th1, Th17, and IL-10-producing T cells. This immune response is partially mediated through signaling pathways involving spleen tyrosine kinase (Syk) and myeloid differentiation primary response gene 88 (MyD88). In mice, sublingual immunization with MV140 promotes the generation of systemic Th1, Th17, and IL-10 immune responses.
Currently, Uromune is in the pre-licensed Phase III development stage. It is available under named patient programs, including compassionate use, in 26 countries worldwide, such as the UK, New Zealand, Netherlands, Germany, Spain, and other Western European countries. Additionally, the company is conducting an expanded access program (NCT04173013) for patients suffering from recurrent/chronic urinary tract infections caused by various factors. This program is aimed at individuals who have not responded to antibiotic therapy.
Stay ahead of the competition by leveraging key insights and evolving trends in the Uromune (MV140) Market @ https://www.delveinsight.com/sample-request/uromune-mv140-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Why Uromune (MV140) Market Report?
Leading Uromune (MV140) for uncomplicated Urinary Tract Infection forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Uromune (MV140)
A thorough Uromune (MV140) market forecast will help understand how the drug is competing with other emerging Uromune (MV140).
Get an analysis of the Uromune (MV140) clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
The report also provides future market assessments for Uromune (MV140) market forecast analysis for uncomplicated Urinary Tract Infection in the 7 Major Markets, advanced qualitative analysis like SWOT, expert analysts' views, a detailed overview of market competitors, and a short analysis of other emerging therapies in uncomplicated Urinary Tract Infection.
Download the sample report to learn more about the evolving market dynamics @ https://www.delveinsight.com/report-store/uromune-mv140-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Related reports:
uncomplicated Urinary Tract Infection Market Report 2032
DelveInsight's "uncomplicated Urinary Tract Infection- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the uncomplicated Urinary Tract Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
uncomplicated Urinary Tract Infection Pipeline 2023
"uncomplicated Urinary Tract Infection Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Onycholysis market. A detailed picture of the Onycholysis pipeline landscape is provided, which includes the disease overview and Onycholysis treatment guidelines.
uncomplicated Urinary Tract Infection Epidemiology 2032
DelveInsight's 'uncomplicated Urinary Tract Infection - Epidemiology Forecast-2032' report delivers an in-depth understanding of the uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the uncomplicated Urinary Tract Infection trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Leading Reports by DelveInsight:
Asthma Diagnostic Devices Market
Chronic Obstructive Pulmonary Disease Treatment Devices Market
Airway Management Devices Market
Cough Assist Devices Market
Pulse Oximeters Market
Hemodialysis Catheter Devices Market
Chronic Spontaneous Urticaria Market
Gender Dysphoria Market
Germany Healthcare Outlook
Biopsy Devices Pipeline Insight
Bacterial Conjunctivitis Market
Infliximab Biosimilar Insight
Eosinophilic Asthma Market
Cushing Syndrome Market
Functional Dyspepsia Market
Peripherally Inserted Central Catheters (PICC) Devices Market
Consulting Services:
DelveInsight's Healthcare Consulting Services offers a comprehensive and customized approach to address the diverse needs of clients in the healthcare sector. These services are specifically designed to tackle the most critical challenges faced by clients while also identifying and capitalizing on emerging opportunities.
By leveraging DelveInsight's deep industry knowledge, extensive market research capabilities, and advanced data analytics, healthcare consulting services provide clients with practical and data-driven solutions. The consultants collaborate closely with clients to gain a thorough understanding of their unique requirements and obstacles, enabling them to develop tailored strategies and solutions. DelveInsight's consulting expertise encompasses various aspects of the healthcare industry, including market access, commercial strategy, product development, and regulatory affairs.
Get in touch today to navigate the complexities of the life sciences industry and successfully achieve your business goals @ https://www.delveinsight.com/consulting
Contact Us:
Kritika Rehani
+91-9650213330
Email: info@delveinsight.com
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uromune (MV140) Drug Market Forecast and Analysis | Uromune (MV140) for uncomplicated Urinary Tract Infection: Market Size Analysis and Competitive Landscape by DelveInsight here
News-ID: 3118042 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Uromune
Uncomplicated Urinary Tract Infection Market Poised for Growth with Rising Aware …
Uncomplicated urinary tract infections (uUTIs), among the most common bacterial infections globally, predominantly affect otherwise healthy individuals, particularly women. Characterized by symptoms like dysuria, frequency, and urgency, uUTIs are generally confined to the lower urinary tract and are managed effectively with antibiotics. However, increasing antibiotic resistance, recurrent infections, and shifting treatment guidelines are reshaping the uncomplicated urinary tract infection market landscape.
DelveInsight's latest report, "Uncomplicated Urinary Tract Infection Market Insight, Epidemiology…
Sulopenem Etzadroxil/Probenecid (orlynvah) by Iterum Therapeutics expected to ch …
Washington, D.C. - DelveInsight, a premier pharmaceutical market research firm, has launched its latest report, "Sulopenem Etzadroxil/Probenecid Market Size, Forecast, and Emerging Insight - 2032." This in-depth analysis delivers crucial insights into the evolving market landscape, clinical advancements, and regulatory trajectory of Sulopenem Etzadroxil/Probenecid-a groundbreaking treatment poised to redefine uncomplicated urinary tract infection (uUTI) management across key global markets.
Request for sample report @ https://www.delveinsight.com/report-store/sulopenem-etzadroxil-probenecid-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Addressing the Growing Burden of uUTIs
Urinary tract…
Uncomplicated Urinary Tract Infections (UTI) Treatment Market 2034: Clinical Tri …
Uncomplicated Urinary Tract Infections Companies are GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, Fimbrion Therapeutics, And Many More
(Albany, USA) DelveInsight's "Uncomplicated Urinary Tract Infections (UTI) Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Uncomplicated Urinary Tract Infections market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany,…
Uromune (MV140) Market Size and Share Analysis Across 7MM and Competitive Landsc …
DelveInsight has released a comprehensive report titled "Uromune (MV140) Market Forecast" offering a thorough examination and predictive insights into the Uromune (MV140) market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of Uromune (MV140) in the therapeutics landscape for uncomplicated Urinary…
The US Urinary Tract Infection Therapeutics Market is expected to reach ~$2Bn by …
The US urinary tract infection therapeutics market is anticipated to grow at a CAGR of ~2% and become a ~USD 2Bn industry by 2028. Currently, this industry has a market size of ~USD1.8 Bn.
STORY OUTLINE
The rising age of the population is one of the major factor responsible for the growth of the US UTI Therapeutics market.
The rise in government expenditure towards the healthcare sector also pose as growth inhibitor for the US…
Uncomplicated Urinary Tract Infections Emerging and Marketed Drugs Assessment (2 …
"Uncomplicated Urinary Tract Infections Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Uncomplicated Urinary Tract Infections Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities…
